Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Acne

Therapeutic area intelligence for Acne with 9 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
9
Catalysts
0
Companies
6

Companies

Acne →
Alembic Pharmaceuticals →
Aurobindo Pharma →
Sun Pharma →
Taro Pharmaceuticals →
Upsher Smith Labs →

Assets

Absorica →
Adapalene →
Bausch →
Dermatology →
FDA →
Galderma →
Isotretinoin →
Tretinoin →
UNIQUE →

Recent signals(9)

CompetitiveJuly 25, 2026

Aurobindo Pharma submits ANDA for Adapalene and Benzoyl Peroxide

Aurobindo Pharma has submitted an Abbreviated New Drug Application (ANDA) for a combination of Adapalene and Benzoyl Peroxide.

RegulatoryJuly 25, 2026

FDA Accepts Supplement Application for Acanya by Bausch

The FDA has accepted a supplemental application for Acanya, a topical acne treatment containing benzoyl peroxide and clindamycin phosphate.

RegulatoryJuly 20, 2026

FDA Approves Differin Epiduo Acne Gel for Acne Treatment

The FDA has approved Differin Epiduo Acne Gel, which contains adapalene and benzoyl peroxide.

StrategyJuly 9, 2026

FDA Grants Approval for Adapalene ANDA219565 by UNIQUE

The FDA has granted approval for ANDA219565, a generic formulation of Adapalene submitted by UNIQUE.

CompetitiveJuly 8, 2026

FDA Submission Update for Azelaic Acid by Taro Pharmaceuticals

Taro Pharmaceuticals has submitted an original application for Azelaic Acid under ANDA212581.

RegulatoryJune 23, 2026

FDA Approval Status Update for Isotretinoin by Upsher Smith Labs

The FDA has granted an Approval Pending (AP) status for the isotretinoin application ANDA213571 submitted by Upsher Smith Labs.

RegulatoryJune 20, 2026

FDA Accepts Supplement Application for Absorica by Sun Pharma

The FDA has accepted a supplemental application for Absorica, an isotretinoin product from Sun Pharma.

RegulatoryJune 18, 2026

FDA Accepts Supplement for ABSORICA LD by Sun Pharma

The FDA has accepted a supplemental application for ABSORICA LD, an isotretinoin product by Sun Pharma.

StrategyJune 18, 2026

FDA Grants Approval for Tretinoin ANDA214590 by Alembic

The FDA has granted approval for Alembic's Abbreviated New Drug Application (ANDA) for Tretinoin.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.